Login to Your Account

Abbvie phase III miss with veliparib puts wrinkle in PARP effort

By Marie Powers
News Editor

Thursday, April 20, 2017

Veliparib, Abbvie Inc.'s only shot at the oral PARP market, failed two key phase III tests, missing the primary endpoints in studies evaluating the agent in combination with carboplatin and paclitaxel in patients with squamous NSCLC and triple-negative breast cancer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription